T Cell Clonal Dynamics Determined by High-Resolution TCR-β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
09 2020
Historique:
received: 21 02 2020
revised: 13 04 2020
accepted: 22 04 2020
pubmed: 18 5 2020
medline: 24 6 2021
entrez: 18 5 2020
Statut: ppublish

Résumé

Delayed reconstitution of the immune system is a long-recognized complication after allogeneic hematopoietic cell transplantation (HCT). Specifically, loss of T cell diversity has been thought to contribute to infectious complications, graft-versus-host disease (GVHD), and disease relapse. We performed serial high-resolution next-generation sequencing of T cell receptor (TCR)-β in 99 related or unrelated donor (57 unrelated, 42 related) allogeneic HCT recipients (55 with reduced-intensity conditioning, 44 with myeloablative conditioning) during the first 3 months after HCT using the immunoSEQ Assay. We measured T cell fraction, clonality (1- Peilou's evenness) and Daley-Smith richness from recipient samples at multiple time points. In agreement with previous studies, we found that although absolute T cell numbers recover relatively quickly after HCT, T cell repertoire diversity remains diminished. Restricted diversity was associated with conditioning intensity, use of antithymocyte globulin, and donor type. Increased number of expanded clones compared to donor T cell clones at day +30 was associated with the incidence of acute GVHD (hazard ratio [HR], 1.11; P = .00005). Even after exclusion of the 12 patients who developed acute GVHD before day +30, the association between acute GVHD and increased clonal expansion at day +30 remained (HR, 1.098; P = .041), indicating that increased clonal T cell expansion preceded the development of acute GVHD. Our results highlight T cell clonal expansion as a potential novel biomarker for acute GVHD that warrants further study.

Identifiants

pubmed: 32417490
pii: S1083-8791(20)30259-7
doi: 10.1016/j.bbmt.2020.04.026
pmc: PMC8279830
mid: NIHMS1720782
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1567-1574

Subventions

Organisme : NCI NIH HHS
ID : T32 CA071345
Pays : United States

Informations de copyright

Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10
pubmed: 26386318
Blood. 2009 Nov 5;114(19):4099-107
pubmed: 19706884
Nat Methods. 2013 Apr;10(4):325-7
pubmed: 23435259
Bone Marrow Transplant. 2015 Sep;50(9):1227-34
pubmed: 26052909
Blood. 2000 Jan 1;95(1):352-9
pubmed: 10607724
Nat Commun. 2013;4:2680
pubmed: 24157944
Leukemia. 2020 May;34(5):1422-1432
pubmed: 31772297
Biol Blood Marrow Transplant. 2006 Mar;12(3):335-45
pubmed: 16503503
JCI Insight. 2016;1(5):
pubmed: 27213183
Chimerism. 2015 Jul 3;6(3):47-9
pubmed: 26745665
Nat Med. 2013 Mar;19(3):372-7
pubmed: 23435170
Biol Blood Marrow Transplant. 2019 May;25(5):868-882
pubmed: 30677510
Haematologica. 2019 Mar;104(3):622-631
pubmed: 30262565
Mol Oncol. 2015 Dec;9(10):2063-70
pubmed: 26404496
J Virol. 2015 Apr;89(8):4517-26
pubmed: 25653453
J Immunol. 2019 Jan 15;202(2):476-483
pubmed: 30541882
Biol Blood Marrow Transplant. 2012 Apr;18(4):565-74
pubmed: 21875503
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Leuk Lymphoma. 2007 Aug;48(8):1618-27
pubmed: 17701594
J Immunol Methods. 2012 Jan 31;375(1-2):14-9
pubmed: 21945395
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269

Auteurs

Mark Leick (M)

Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.

Rachel M Gittelman (RM)

Adaptive Biotechnologies, Seattle, Washington.

Erik Yusko (E)

Adaptive Biotechnologies, Seattle, Washington.

Catherine Sanders (C)

Adaptive Biotechnologies, Seattle, Washington.

Harlan Robins (H)

Adaptive Biotechnologies, Seattle, Washington.

Zachariah DeFilipp (Z)

Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.

Sarah Nikiforow (S)

Division of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.

Jerome Ritz (J)

Division of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.

Yi-Bin Chen (YB)

Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ychen6@partners.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH